Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYingying YeJLJun LuoHWHua Wang

Discussion

Loading...

Member takes

Overview

Retrospective study shows effective renal and hematologic response in patients with NDMM and renal impairment, highlighting the role of daratumumab.

Key Points

  • Renal and hematologic response rates are high with daratumumab-based regimens in newly diagnosed multiple myeloma patients.
  • The study reports a renal overall response rate of 76.4% at three months, with significant overall survival observed.
  • Data were collected from a multicenter retrospective analysis focusing on patients with renal impairment based on specific criteria.
  • Findings indicate that daratumumab combinations are very effective first-line treatments for NDMM patients with renal impairment.

Cite This Study

Ye et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e25bhttps://doi.org/10.1182/blood-2025-7546
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab‐Based Combinational Therapy as Second‐Line Treatment of Relapsed‐Refractory Multiple Myeloma: A Single‐Center Experience2025
  2. 2Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results2025
  3. 3Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY40322025
  4. 4Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myeloma2025
  5. 5Better renal response with daratumumab in patients with monoclonal immunoglobulin deposition disease2025